Premium
Proliferation marker MIB‐1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c‐erbB‐2 and estrogen receptor status
Author(s) -
Moriki Toshiaki,
Takahashi Tamotsu,
Kataoka Hiromi,
Hiroi Makoto,
Yamane Toshiko,
Hara Hiroshi
Publication year - 1996
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.1996.tb03574.x
Subject(s) - proliferating cell nuclear antigen , immunohistochemistry , pathology , estrogen receptor , proliferation marker , breast cancer , erbb , biology , estrogen , medicine , cancer
The proliferative activity of 30 cases of non‐treated invasive ductal breast carcinoma was evaluated by bromodeoxyuri‐dine (BrdU), proliferation marker (MIB‐1) and proliferating cell nuclear antigen (PCNA), and the relation between these proliferation markers and histologlcal subtype and histolog‐ical grade were investigated. In addition, the association of these proliferation markers with overexpression of p53 protein, c‐erbB‐2 oncoprotein, estrogen receptor (ER) status and clinicopathologic findings were also examined. The BrdU labeling index (LI), MIB‐1 score and PCNA labeling rate (LR) correlated with the histological grade. However, there was no statistical difference in proliferative activity among the histological subtypes. A linear strong correlation was demonstrated between BrdU Li and MIB‐1 score (r=0.732). Significant correlation was also found between BrdU LI and PCNA LR (r=0.446); however, the relation between MIB‐1 score and PCNA LR was weak. BrdU LI and MIB‐1 score correlated positively with tumor size, TNM stage and over‐expression of p53, and negatively with the presence of ER. PCNA LR correlated only with p53. These results indicate that MIB‐1 is closely associated with BrdU in clinicopathologic findings and is a more useful tool for evaluating cell proliferation than PCNA. However, it will be necessary to consider the clinical significance of MIB‐1 immunohisto‐chemistry cautiously until further widespread clinical and pathological studies are performed.